Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

nj46nick 80 posts  |  Last Activity: 15 hours ago Member since: Feb 1, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • nj46nick nj46nick 15 hours ago Flag

    Excellent find! Best to you and all Longs!

    Sentiment: Strong Buy

  • Reply to

    Standing

    by longtimetrader Mar 27, 2015 10:53 AM
    nj46nick nj46nick Mar 27, 2015 11:02 AM Flag

    How low is this going?

    Sentiment: Buy

  • nj46nick nj46nick Mar 27, 2015 10:18 AM Flag

    Fading..... Watch for him!

  • nj46nick nj46nick Mar 27, 2015 9:17 AM Flag

    Watch out for him, he is slick! Lesson learned already! I'm on the sidelines just waiting! Best to you!

    Sentiment: Buy

  • nj46nick by nj46nick Mar 26, 2015 10:13 AM Flag

    Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia

    Sentiment: Strong Buy

  • nj46nick by nj46nick Mar 25, 2015 7:43 AM Flag

    Upcoming event seems very promising! Best to all!

    Sentiment: Strong Buy

  • Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31

    Sentiment: Strong Buy

  • Reply to

    Both deals set to close soon

    by shmibblebop Mar 24, 2015 9:50 AM
    nj46nick nj46nick Mar 24, 2015 12:04 PM Flag

    Very well spoken! I wish you the very best!

  • nj46nick by nj46nick Mar 23, 2015 8:08 AM Flag

    Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015

    Sentiment: Strong Buy

  • Reply to

    SD trans to PVA

    by lapieredonald Mar 13, 2015 10:41 AM
    nj46nick nj46nick Mar 13, 2015 10:57 AM Flag

    Listen just for your info. I follow this fellow moon_shine15 on tw He's been spot on! Best to ya!

    Sentiment: Strong Buy

  • Reply to

    SD trans to PVA

    by lapieredonald Mar 13, 2015 10:41 AM
    nj46nick nj46nick Mar 13, 2015 10:45 AM Flag

    6.20

  • nj46nick by nj46nick Mar 13, 2015 8:37 AM Flag

    http://finance.yahoo.com/news/american-green-activates-first-machines-123000130.html

  • nj46nick by nj46nick Mar 13, 2015 8:36 AM Flag

    American Green Activates the First Machines in Its ZaZZZ Network -- Provides First Look at Verification Interface

  • Reply to

    News!

    by nj46nick Feb 25, 2015 8:08 AM
    nj46nick nj46nick Feb 25, 2015 8:08 AM Flag

    Medican Enterprises Inc. (MDCN), announced today that the 67,000 square foot facility located, in Phoenix Arizona, it is acquiring has received zoning approval and is now zone compliant for the operation of legal #$%$ businesses.

    “With the zoning approval in hand, this commercial transaction now meets our criteria and we are moving rapidly to finalize the due diligence process,” commented Ken Williams, CEO of Medican Enterprises. “Located just minutes from Hwy 60 and the I-17 and featuring excellent visibility in a high traffic center, this unique property represents the type of asset we are looking for.”

    The transaction is planned for closure by the end of the first quarter of 2015.

    Sentiment: Hold

  • nj46nick by nj46nick Feb 25, 2015 8:08 AM Flag

    Medican Enterprises Announces Zoning Approval for Marijuana Business Operations in 67,000 Square Foot Arizona Property

    Sentiment: Hold

  • nj46nick by nj46nick Feb 23, 2015 8:33 AM Flag

    Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
    Download PDF
    SAN FRANCISCO and GENEVA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that its abstract titled, "The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.

    The poster will highlight the positive data analysis of whole blood samples from 140 subjects (71 Alzheimer's disease and 69 age matched controls) using the company's LymPro Test blood-based assay for Alzheimer's disease (AD). The LymPro Test measures lymphocyte proliferation in response to a mitogenic stimulus and quantifies the extent to which lymphocytes have entered the cell division cycle. Cell cycle dysregulation in neurons is a key pathology in AD, that results in neuronal death and cognitive decline. In the LymPro test, lymphocyte measurements are used as a surrogate for this neuronal cell dysfunction. The analysis demonstrates that, in combination with standard of care clinical measurements, LymPro can give physicians greater confidence that an Alzheimer's diagnosis is truly accurate.

    "We are very pleased to have this confirmatory LymPro abstract accepted for a poster session at one of the premiere scientific congresses focused on neurological disorders," said Gerald E. Commissiong, President & CEO of Amarantus BioSciences Holdings, Inc. "We believe the LymPro Test is an important leading Alzheimer's biomarker assay and is a key diagnostic asset for advancing robust therapeutic clinical studies in Alzheimer's disease. This conference will provide important exposure as we continue building a significant customer base for blood-based biomarker services in Alzheimer's disease, with the ultimate shared goal of improving the current standard of care used to treat AD."

    The poster data to be presented at AD/PD 2015 by Louis Kirby, Corporate Advisor and Medical Director of Amarantus Diagnostics, confirms the consistent and accurate ability of the LymPro Test to distinguish univariate and multivariate combination indicators of lymphocyte proliferation AD biomarkers from controls. Additionally, the analysis corroborates two previous peer-reviewed publications in which data from the Company's recently completed LP-002 clinical study established the LymPro Test as an advantageous diagnostic that can serve as the first step in a multistep diagnostic process for early identification of Alzheimer's disease.

    Sentiment: Strong Buy

  • Reply to

    Serious Question

    by nj46nick Feb 21, 2015 8:28 AM
    nj46nick nj46nick Feb 22, 2015 5:23 PM Flag

    Good to know, thanks
    Best to ya

    Sentiment: Buy

  • Reply to

    Serious Question

    by nj46nick Feb 21, 2015 8:28 AM
    nj46nick nj46nick Feb 22, 2015 2:43 PM Flag

    Sent ya a tweet! Sorry for the spelling in the above reply! Typist I'm not!

  • Reply to

    Serious Question

    by nj46nick Feb 21, 2015 8:28 AM
    nj46nick nj46nick Feb 22, 2015 2:38 PM Flag

    I will check them out, st is stock twits. I f I like a stock I will go on there and check out some of the commentary....it is still picking and choosing however. Some individuals are worht following. I was invested in a bio tech, followed the company on Stock Twits and managed to block over 7 pages worth of folks! LOL! I will continue to delve into all the leads you gave me. As I said before, I still have some time to decide. Thank you for all your help. I'll check ya out on twtr. Nick

    Sentiment: Buy

  • Reply to

    Serious Question

    by nj46nick Feb 21, 2015 8:28 AM
    nj46nick nj46nick Feb 22, 2015 6:14 AM Flag

    William, do you mind if I pick your brain one more time? What are your viewpoints both negative and positive for $OIL? Seems to be in a good position for investment purposes.Also if you are on twtr or ST let me know. I would follow ya. Have a great day! Many thanks!

    Sentiment: Buy

AMBS
0.050.00(-2.34%)Mar 31 3:59 PMEDT